Physician profile
Jay A Passmore
NPI 1063804532
$12,591.30
in general payments reported to CMS, 2019-2025
33 companies · $4,236 in 2025
The $4,236 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,634 · 2022: $2,234 · 2023: $2,003 · 2024: $2,485 · 2025: $4,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,202 · Consulting Fee: $1,125 · Education: $396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,201.56 |
| Consulting Fee | $1,125.00 |
| Education | $396.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $2,450.10 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $2,067.37 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $1,374.64 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $976.63 | 2021-2025 | |
| Lilly USA, LLC | $930.06 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $893.15 | 2021-2025 | Ilumya |
| Genzyme Corporation | $829.63 | 2021-2025 | |
| Ucb, INC. | $391.09 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $345.98 | 2022-2025 | |
| Dermavant Sciences, INC. | $318.46 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $290.56 | 2023-2025 | Nemluvio, Oracea, Aklief |
| Incyte Corporation | $281.83 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $205.61 | 2021-2024 | Adbry |
| Amgen INC. | $202.91 | 2021-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $149.44 | 2023-2025 | Zoryve |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.63 | 2022-2025 | Spevigo |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Mayne Pharma Commercial LLC | $93.24 | 2022-2024 | |
| Mallinckrodt Hospital Products INC. | $93.14 | 2024-2025 | Acthar |
| Organon LLC | $72.85 | 2025 | Vtama |
| Biofrontera INC. | $55.60 | 2024-2025 | Xepi, Bf-Rhodoled, Rhodoled Xl |
| Abbott Laboratories | $48.86 | 2021 | |
| Vyne Pharmaceuticals INC. | $39.91 | 2021 | |
| Paratek Pharmaceuticals, INC. | $34.99 | 2024-2025 | Nuzyra |
| Genentech USA, INC. | $34.36 | 2021 | |
| Convatec INC. | $33.24 | 2024 | |
| Kyowa Kirin, INC. | $27.09 | 2023 | Poteligeo |
| Almirall LLC | $26.25 | 2024 | Seysara |
| Kerecis Limited | $22.56 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Fresenius Kabi USA, LLC | $20.95 | 2024 | |
| Smith+Nephew, INC. | $19.97 | 2023 | Collagenase Santyl |
| Epi Health, LLC | $19.27 | 2022 | |
| Verrica Pharmaceuticals INC. | $18.94 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Passmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.